Intercept Pharmaceuticals, Inc. (ICPT) Stock Rating Reaffirmed by Jefferies Group LLC

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “buy” rating restated by analysts at Jefferies Group LLC in a report issued on Wednesday. They presently have a $275.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price target indicates a potential upside of 180.27% from the stock’s previous close.

Several other equities analysts have also commented on the stock. Citigroup Inc. reaffirmed a “buy” rating and set a $150.00 target price on shares of Intercept Pharmaceuticals in a report on Tuesday. Wedbush reaffirmed an “ourperform” rating and set a $253.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, September 15th. Royal Bank Of Canada assumed coverage on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $244.00 target price on the stock. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Finally, Cowen and Company reissued an “outperform” rating and issued a $232.00 price target on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $202.45.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 2.00% during trading on Wednesday, hitting $98.12. 634,601 shares of the stock were exchanged. The stock’s 50 day moving average price is $106.75 and its 200 day moving average price is $115.74. The firm’s market capitalization is $2.46 billion. Intercept Pharmaceuticals has a 52 week low of $85.88 and a 52 week high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. During the same quarter last year, the firm earned ($3.14) EPS. The firm’s quarterly revenue was up 459.6% compared to the same quarter last year. On average, equities analysts predict that Intercept Pharmaceuticals will post ($13.91) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://sportsperspectives.com/2017/09/20/intercept-pharmaceuticals-inc-icpt-stock-rating-reaffirmed-by-jefferies-group-llc.html.

In related news, Director Daniel G. Welch sold 217 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the completion of the sale, the director now directly owns 3,710 shares in the company, valued at $470,279.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO David Shapiro sold 1,250 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $117.43, for a total transaction of $146,787.50. Following the sale, the chief marketing officer now owns 45,812 shares of the company’s stock, valued at $5,379,703.16. The disclosure for this sale can be found here. Insiders sold 48,013 shares of company stock valued at $6,198,747 over the last quarter. Company insiders own 4.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. WFG Advisors LP grew its position in Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the period. Dynamic Technology Lab Private Ltd grew its position in Intercept Pharmaceuticals by 85.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock valued at $824,000 after buying an additional 3,136 shares during the period. Public Employees Retirement System of Ohio grew its position in Intercept Pharmaceuticals by 15.0% during the second quarter. Public Employees Retirement System of Ohio now owns 7,385 shares of the biopharmaceutical company’s stock valued at $894,000 after buying an additional 965 shares during the period. Asymmetry Capital Management L.P. bought a new stake in Intercept Pharmaceuticals during the second quarter valued at approximately $3,580,000. Finally, Nomura Holdings Inc. bought a new stake in Intercept Pharmaceuticals during the second quarter valued at approximately $366,000. Institutional investors own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply